Brain Cancer Clinical Trials in Cleveland

Showing 101-120 of 224 trials

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

NCT04013672

The main purpose of this study is to assess the clinical activity of Pembrolizumab and SurVaxM in participants with recurrent glioblastoma.

Recurrent Glioblastoma

David Peereboom41 participantsStarted Mar 2020

Cleveland, Ohio, United States

TERMINATEDPhase 1< 1 mile

Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT03250299

This Phase I study investigated the side-effects and best dose of microtubule-targeted agent BAL101553 when given together with radiation therapy in treating patients with newly-diagnosed O6-methylguanine-DNA methyltransferase (MGMT) promoter unmethylated glioblastoma (GBM). Drugs used in chemotherapy, such as microtubule-targeted agent BAL101553, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving microtubule-targeted agent BAL101553 and radiation therapy may work better in treating patients with GBM.

GlioblastomaMGMT-Unmethylated Glioblastoma

Basilea Pharmaceutica26 participantsStarted Dec 2017

Birmingham, Alabama, United States • Baltimore, Maryland, United States • Boston, Massachusetts, United States +5 more locations

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Brain Cancer Trials in Other Cities

Laser Ablation After Stereotactic Radiosurgery

Feasibility Study on LITT for Newly Diagnosed Glioblastoma

Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

Other Conditions in Cleveland